Suicidal ideation in patients with chronic pain: The risk-benefit of pharmacotherapy

Pain

Volumn 155, Issue 12, 2014, Pages 2446-2447

  Cheatle, Martin D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; OPIATE;

ANXIETY DISORDER; BEHAVIOR CHANGE; CHRONIC PAIN; CHRONIC PATIENT; DISEASE ASSOCIATION; DRUG MISUSE; DRUG OVERDOSE; HIGH RISK PATIENT; HUMAN; MOOD DISORDER; NOTE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK BENEFIT ANALYSIS; RISK FACTOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; COMPLICATION; DEPRESSION; PSYCHOLOGY;

ANTIDEPRESSIVE AGENTS; CHRONIC PAIN; DEPRESSION; HUMANS; SUICIDAL IDEATION; SUICIDE, ATTEMPTED;

EID: 84922717365     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2014.09.032     Document Type: Editorial

References (10)

1. Calandre E, Navajas-Rojas M, Ballesteros J, Garcia-Carrillo J, Garcia-Leiva J, Rico-Villademoros F. Suicidal ideation in patients with fibromyalgia: A cross-sectional study. Pain Pract 2014 [Epub ahead of print].
2. Fishbain DA, Lewis JE, Gao J. The pain suicidality association: A narrative review. Pain Med 2014. http://dx.doi.org/10.1111/pme.12463 [Epub ahead of print].
3. Hitchcock L, Ferrell B, McCaffery M. The experience of chronic nonmalignant pain. J Pain Symptom Manage 1994;9:312-8.
4. Lee D, Noh E, Kim Y, Hwang J, Kim S, Jang J, Byun M, Kang D. Risk factors for suicidal ideation among patients with complex regional pain syndrome. Psychiatry Investig 2014;11:32-8.
5. ® 1993;53:163-8.
6. ® 2014;155:2471-5.
7. ® 2013;153:345-9.
8. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-77.
9. Tang NK, Crane C. Suicidality in chronic pain: A review of the prevalence, risk factors and psychological links. Psychol Med 2006;36:575-86.
10. US Food and Drug Administration. Guidance for industry: Suicidal ideation and behavior: Prospective assessment of occurrence in clinical trials, available at: ; 2014 [Accessed 09.011.14].